Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for Social Anxiety Disorder and comorbid disorders: A randomized controlled trial  by Dear, B.F. et al.
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Disorder-speciﬁc  (DS-CBT)  and transdiagnostic  (TD-CBT)  cognitive  behaviour  therapy  have  both  been
used  to treat  social  anxiety  disorder  (SAD).  This  study  compared  internet-delivered  DS-CBT  and  TD-
CBT  for  SAD  across  clinician-guided  (CG-CBT)  and  self-guided  (SG-CBT)  formats.  Participants  with  SAD
(n = 233)  were  randomly  allocated  to receive  internet-delivered  TD-CBT  or DS-CBT  and  CG-CBT  or  SG-CBT.
Large  reductions  in  symptoms  of SAD  (Cohen’s  d  ≥ 1.01;  avg.  reduction  ≥  30%)  and moderate-to-large
reductions in  symptoms  of  comorbid  depression  (Cohen’s  d  ≥ 1.25;  avg. reduction  ≥ 39%), generalised
anxiety  disorder  (Cohen’s  d  ≥  0.86;  avg.  reduction  ≥  36%)  and  panic  disorder  (Cohen’s  d  ≥ 0.53;  avg.
reduction  ≥  25%)  were  found  immediately  post-treatment  and  were  maintained  or  further  improved
to  24-month  follow-up.  No  marked  differences  were  observed  between  TD-CBT  and  DS-CBT  or  CG-CBT
and  SG-CBT  highlighting  the  potential  of each  for the treatment  of  SAD  and comorbid  disorders.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd. This  is an open  access  article  under  the  CC  BY-NC-ND
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. Introduction
Social Anxiety Disorder (SAD) is a common anxiety disorder
haracterized by an excessive fear of being embarrassed or humil-
ated in social situations (American Psychiatric Association, 2013).
he 12-month prevalence of SAD is 4.4% in Australia and has an esti-
ated lifetime prevalence of 7.2% (McEvoy, Grove, & Slade, 2011).
oth clinical and subthreshold SAD cause signiﬁcant functional
mpairment and are highly comorbid with other anxiety disorders
nd depression (Fehm, Beesdo, Jacobi, & Fiedler, 2008).
Cognitive behavioural therapy (CBT) has demonstrated efﬁ-
acy in treating SAD and can be administered face-to-face (Butler,
hapman, Forman, & Beck, 2006; Stewart & Chambless 2009;
offman, Asnaani, Vonk, Sawyer, & Fang, 2012; Acarturk, Cuijpers,
∗ Corresponding author at: eCentreClinic, Department of Psychology, Macquarie
niversity, New South Wales, Australia.
E-mail address: blake.dear@mq.edu.au (N. Titov).
ttp://dx.doi.org/10.1016/j.janxdis.2016.05.004
887-6185/© 2016 The Author(s). Published by Elsevier Ltd. This is an open access articl
.0/).van Straten, & de Graaf, 2009) and via the internet (Andersson et al.,
2006; Titov et al., 2009; Andersson & Titov 2014a,b; El Alaoui et al.,
2015). Reﬂecting this, recent meta-analyses of studies directly com-
paring face-to-face and clinician-guided internet-delivered CBT for
common anxiety and depressive disorders, including SAD, indicate
that both methods of delivery are associated with similar clinical
outcomes (Andersson, Cuijpers, Carlbring, Riper, & Hedman, 2014).
CBT for SAD aims to treat symptoms by addressing maladaptive
cognitions and behaviours, which maintain SAD, and teaches skills
designed to reduce unhelpful patterns of thought and behaviour
(Clark & Wells 1995).
CBT interventions traditionally target symptoms of one disorder
at a time; this approach is sometimes referred to as disorder-
speciﬁc (McEvoy, Nathan, & Norton, 2009;McManus, Shafran, &
Cooper, 2010; Titov, Dear, Johnston, & Terides, 2012a,b). An alter-
native approach is to simultaneously treat both principal and
comorbid anxiety and depressive disorders by targeting common
symptoms and underlying psychological processes; this approach
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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s known as transdiagnostic (Barlow, Allen, & Choate, 2004; McEvoy
t al., 2009; McHugh, Murray, & Barlow, 2009;Titov et al., 2012a,b).
f efﬁcacious and acceptable, the transdiagnostic approach offers
otential pragmatic advantages over disorder-speciﬁc treatments,
ncluding simpliﬁed treatment planning and provision by having
ne treatment that is suitable for a large number of patients irre-
pective of their principal and comorbid disorders (McHugh et al.,
009; Titov et al., 2012a,b). These advantages are particularly sig-
iﬁcant in the context of recent calls for innovation in psychological
reatment (e.g., Kazdin and Blasé, 2011; Kazdin, 2015) and large-
cale initiatives to increase access to treatment for common mental
ealth conditions, such as SAD (e.g., Titov, Dear, Staples, Bennett-
evy et al., 2015; Titov, Dear, Staples, Terides et al., 2015; Richards
nd Suckling, 2009).
Results from several clinical trials indicate that transdiagnos-
ic CBT is clinically effective for SAD (Newby, McKinnon, Kuyken,
ilbody, & Dalgleish, 2015) as well as generalised anxiety disor-
er (GAD) (Dear, Gandy et al., 2015; Dear, Staples et al., 2015;
ear, Zou et al., 2015), major depressive disorder (MDD) (Titov,
ear, Staples, Bennett-Levy et al., 2015; Titov, Dear, Staples, Terides
t al., 2015) and panic disorder (PD) (Fogliati, Dear et al., 2016). To
ate, however, few studies have directly compared the clinical efﬁ-
acy and acceptability of transdiagnostic and disorder-speciﬁc CBT
reatments for SAD. A recent study (n = 46) randomly allocated par-
icipants to receive either a single transdiagnostic CBT treatment or
o one of three disorder-speciﬁc treatments for SAD, GAD, and PD
ith allocation determined by the participant’s principal disorder.
n this study non-inferiority analyses failed to demonstrate signif-
cant differences between the two approaches in outcome (Norton
 Barrera 2012).
The present study is one of a series of four large randomized
ontrolled trials (RCTs) that explore the relative clinical efﬁcacy
nd acceptability of internet-delivered transdiagnostic CBT and
isorder-speciﬁc CBT, when provided in both clinician-guided and
elf-guided formats. The other three RCTs allocated participants
ith principal MDD  (n = 290), principal GAD (n = 338) and principal
D (n = 145) to receive either transdiagnostic or disorder-speciﬁc
reatment and to receive treatment with or without clinician guid-
nce (Dear, Gandy et al., 2015; Dear, Staples et al., 2015; Dear, Zou
t al., 2015; Titov, Dear, Staples, Bennett-Levy et al., 2015; Titov,
ear, Staples, Terides et al., 2015; Fogliati, Dear et al., 2016). Partic-
pants in these trials reported signiﬁcant reductions in symptoms
f MDD, GAD, SAD and PD, which were maintained at 24-month
ollow-up. No marked differences were observed between par-
icipants receiving disorder-speciﬁc or transdiagnostic treatment
t post-treatment, 3-, 12- and 24-month follow-up. Similarly, no
ifferences were found between the types of guidance. These ﬁnd-
ngs provide further evidence for the efﬁcacy of a transdiagnostic
pproach and the potential of carefully-designed self-guided treat-
ents.
The present study employed the same design as the other three
rials and speciﬁcally sought to examine the relative clinical efﬁcacy
nd acceptability of transdiagnostic (TD-CBT) and disorder-speciﬁc
DS-CBT) for principal SAD, when provided in both clinician-guided
CG-CBT) and self-guided (SG-CBT) formats. It was hypothesised
hat both TD-CBT and DS-CBT would result in similarly signiﬁ-
ant reductions in symptoms of SAD. However, by virtue of being
esigned to target the symptoms of multiple disorders, it was
ypothesised that TD-CBT would be superior at reducing symptoms
f comorbid depression, generalised anxiety and panic disorder at
ach time point. It was also hypothesised that CG-CBT would be
uperior to SG-CBT at every time point for both symptoms of SAD
nd comorbid depression, generalised anxiety, and panic symp-
oms. Disorders 42 (2016) 30–44 31
2. Method
2.1. Participants
The study was  approved by the Human Research Ethics Com-
mittee (HREC) of Macquarie University, Sydney, Australia, and the
trial was registered on the Australian and New Zealand Clinical
Trials Registry (ANZCTR) as ACTRN12612000430831. The study
was promoted via advertisements in major newspapers across
Australia and via unpaid general advertisements by a broad range
of non-governmental organisations providing services to people
with mental health difﬁculties. This study was advertised alongside
three other studies with the same design, with each RCT targeting
people with one of four principal diagnoses; that is, MDD, GAD,
SAD and PD. Participants read about the study and applied to par-
ticipate via the website of the eCentreClinic (www.ecentreclinic.
org), which is a specialist research unit offering the opportunity
to receive free psychological treatment via the internet. Interested
individuals were invited to submit an online application to par-
ticipate in the trial, which involved completing several symptom
questionnaires, and providing basic demographic information and
contact details.
The inclusion criteria for the study were: (i) resident of Australia
aged 18–64 years of age; (ii) principal symptoms consistent with
Social Anxiety Disorder; (iii) total score ≥6 on the Mini-Social Pho-
bia Inventory (MINI-SPIN) (Kroenke, Spitzer, & Williams, 2001a,b);
and (iv) if taking medication for anxiety or depression, being on
a stable dose for at least one month. The exclusion criteria were:
(i) experiencing an unmanaged psychotic illness; (ii) experiencing
very severe symptoms of depression i.e., deﬁned as a total score >22
or endorsing a score >2 to item 9 of the Patient Health Question-
naire 9-item (PHQ9); (iii) having a history of self-harm or suicide
attempts within the last 12 months; or (iv) currently participating
in CBT.
The CONSORT ﬂowchart for this trial is shown in Fig. 1. A total
of 370 people applied to participate in the trial and indicated that
symptoms of SAD were their principal difﬁculty during the online
application process. Of these, 293 met  the initial inclusion criteria,
which were assessed via the online application, and then partici-
pated in a telephone interview during which the Mini International
Neuropsychiatric Interview Version 5 (MINI) (Lecrubier et al., 1997)
was administered and the inclusion criteria re-assessed. A further
23 applicants initially indicated principal difﬁculties of MDD, GAD,
or PD, during the online application but, upon interview, indicated
SAD was  their principal difﬁculty. A total of 233 applicants met all
inclusion criteria following the telephone interview. Demographic
and diagnostic characteristics of the resultant sample are shown in
Table 1.
2.2. Design and measures
The study employed a CONSORT-revised compliant RCT in
which participants were randomized to receive one of two treat-
ment approaches (Treatment Approach: TD-CBT vs DS-CBT) and
one of two  support formats (Support Format: CG-CBT vs SG-CBT).
All participants completed questionnaires at initial assessment,
pre-treatment, post-treatment and at 3, 12, and 24-month follow-
up. The primary and secondary measures were administered at
each time point with the exception of the PDSS-SR, which due to an
administrative error was not administered at initial assessment but
was administered at all other time-points. In addition, the PHQ-9
was also administered weekly during treatment. To reduce burden
on participants, the tertiary outcomes were not administered at ini-
tial assessment and the K-10 and NEO-FF-N were not administered
at 24-month follow-up. All analyses, except those for the PDSS-SR
and the tertiary measures, used the initial assessment scores as
32
 
B.F.
 D
ear
 et
 al.
 /
 Journal
 of
 A
nxiety
 D
isorders
 42
 (2016)
 30–44
Table 1
Demographic characteristics of the participants.
Treatment Approach Support Format
Overall (n = 220) TD-CBT (n = 105) DS-CBT (n = 115) Signiﬁcance CG-CBT (n = 112) SG-CBT (n = 108) Signiﬁcance
Gender
Male 92 (42%) 47 (45%) 45 (39%) Wald’s 2 = 0.72, p = 0.397 42 (38%) 50 (46%) Wald’s 2 = 1.76, p = 0.184
Female  128 (58%) 58 (55%) 70 (61%) 70 (63%) 58 (54%)
Age  (years)
Mean (SD) 41.57 (10.89) 41.48 (11.04) 41.65 (10.80) Wald’s 2 = 0.01, p = 0.904 41.22 (9.56) 41.93 (12.15) Wald’s 2 = 0.23, p = 0.631
Range  19 to 64 19 to 64 19 to 64 20 to 62 19 to 64
Marital Status
Single/Never Married 78 (36%) 39 (37%) 39 (34%) Wald’s 2 = 0.65, p = 0.419 41 (37%) 37 (34%) Wald’s 2 = 0.14, p = 0.712
Married/De Facto 128 (58%) 61 (58%) 67 (58%) 61 (55%) 67 (62%)
Separated/Divorced/Widowed 14 (6%) 5 (5%) 9 (8%) 10 (9%) 4 (4%)
Education
High  School or less 32 (15%) 10 (10%) 22 (19%) Wald’s 2 = 1.45, p = 0.228 15 (13%) 17 (16%) Wald’s 2 = 0.84, p = 0.360
Trade/Technical Certiﬁcate 44 (20%) 25 (24%) 19 (17%) 20 (18%) 24 (22%)
Diploma/Degree 144 (66%) 70 (67%) 74 (64%) 77 (69%) 67 (82%)
Employment
Full-time/Part-time 32 (15%) 10 (10%) 22 (19%) Wald’s 2 =0.11, p = 0.738 83 (74%) 74 (69%) Wald’s 2 = 0.82, p = 0.364
Student  44 (20%) 25 (24%) 19 (17%) 8 (7%) 9 (8%)
Unemployed, retired or disabled 144 (66%) 70 (68%) 74 (64%) 21 (19%) 25 (23%)
Previous  Mental Health Treatment 143 (65%) 68 (65%) 75 (65%) Wald’s 2 =0.01, p = 0.944 70 (63%) 73 (68%) Wald’s 2 =0.63, p = 0.428
Currently  Taking Medication 62 (28%) 33 (31%) 29 (25%) Wald’s 2 = 1.05, p = 0.305 36 (32%) 26 (24%) Wald’s 2 = 1.78, p = 0.182
Note. TD = transdiagnostic, DS = disorder-speciﬁc, CG = clinician-guided, SG = self-guided, CBT = cognitive behaviour therapy.
B.F. Dear et al. / Journal of Anxiety Disorders 42 (2016) 30–44 33
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uFig. 1. Participant ﬂow from aaseline. Unblinded MINI diagnostic assessments were conducted
ia telephone at initial assessment and again at 3-month follow-
p. The study was powered for comparisons between the twoation to 24-month follow-up.treatment approaches and between the two delivery formats. The
researchers sought to recruit at least 102 participants for each com-
parison arm (i.e., TD-CBT vs DS-CBT and CG-CBT vs SG-CBT) which,
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ith alpha set at 0.05 and power set at 0.80, would enable the detec-
ion of small-to-moderate effect size differences between the arms
i.e., Cohen’s ds > 0.35). However, more participants were recruited
o address both expected treatment withdrawal and questionnaire
on-response at post-treatment time points.
.2.1. Primary measure
.2.1.1. Mini-social phobia inventory (Mini-SPIN) (Connor, Kobak,
hurchill, Katzelnick, & Davidson, 2001). The MINI-SPIN is a brief,
-item, measure of social anxiety symptoms based on DSM-IV crite-
ia for SAD (Connor et al., 2001; Weeks, Spokas, & Heimberg, 2007;
sorio, Crippa, & Loureiro, 2010). The MINI-SPIN has strong inter-
al consistency and adequate convergent validity with other longer
easures of social anxiety symptoms, including the Liebowitz
ocial Anxiety Scale (Liebowitz 1987) and Social Interaction Anxi-
ty Scale (Mattick & Clarke 1998), as well as clinician administered
iagnostic assessments (Weeks et al., 2007; Fogliati et al., in press).
he MINI-SPIN was selected over longer measures in order to
educe burden on participants across the study. Scores range from
 to 12 and Cronbach’s  in this study was 0.75.
.2.2. Secondary measures
.2.2.1. Generalized anxiety disorder 7-item scale (GAD-7) (Spitzer,
roenke, Williams, & Löwe, 2006).). The GAD-7 is a 7-item measure
f the symptoms and severity of general anxiety, which is based on
he DSM-IV diagnostic criteria for GAD (Löwe et al., 2008). The GAD-
 has good internal consistency and good convergent and divergent
alidity with other anxiety and disability scales (Kroenke, Spitzer,
 Williams, 2010a,b; Dear et al., 2011). Scores range from 0 to 21
nd Cronbach’s  in the current study was 0.86.
.2.2.2. Patient health questionnaire-9 item (PHQ-9) (Kroenke et al.,
001a,b). The PHQ-9 is a 9-item measure of symptoms of depres-
ion based on the DSM-IV diagnostic criteria for major depressive
isorder (Kroenke et al., 2001a,b). The PHQ-9 has good internal con-
istency (Titov et al., 2011) and is sensitive to change (Kroenke et al.,
010a,b). Scores range from 0 to 27 and Cronbach’s  in this study
as 0.83.
.2.2.3. Panic disorder severity scale − self report (PDSS-SR) (Houck,
piegel, Shear, & Rucci, 2002). The PDSS-SR is a 7-item measure of
anic disorder symptoms. Psychometric evaluations suggest that
t has high internal consistency, good test-retest reliability and is
ensitive to treatment-related change (Houck et al., 2002). Scores
ange from 0 to 28 and Cronbach’s  in the current study was 0.94
.2.3. Tertiary measures
.2.3.1. Kessler 10-item scale (K-10) (Kessler et al., 2002). The K-10
s a ten-item measure of general psychological distress with total
cores ≥ 22 associated with a diagnosis of anxiety and depressive
isorders (Andrews and Slade 2001). Scores range from 0 to 50 and
ronbach’s  in the current study was 0.89.
.2.3.2. Sheehan disability scale (SDS) (Sheehan 1983). The SDS is a
-item measure of disability with high internal consistency (Leon,
lfson, Portera, Farber, & Sheehan, 1997). Scores range from 0 to
0 and Cronbach’s  in the present study was 0.79.
.2.3.3. NEO-Five factor inventory − neuroticism subscale (NEO-FFI-
 (Costa and McCrae, 1985). The Neuroticism subscale of the NEO
s a 12-item measure of a general tendency to experience negative
motional states and sensitivity to stress (Clark, Watson, & Mineka,
994; Grifﬁth et al., 2010), which is considered a higher-order risk
actor for anxiety and depression (Cuijpers, van Straten, & Donker, Disorders 42 (2016) 30–44
2005; Spinhoven, de Rooij, Heiser, Smit, & Penninx, 2009). Scores
range from 0 to 48 and Cronbach’s  in the current study was 0.77.
2.2.4. Other measures
2.2.4.1. Mini international neuropsychiatric interview version 5.0.0
(MINI) (Lecrubier et al., 1997). The MINI is a brief diagnos-
tic interview developed to determine the presence of current
Axis-I disorders using DSM-IV diagnostic criteria. It has excel-
lent inter-rater reliability and adequate concurrent validity with
the Composite International Diagnostic Interview (World Health
Organization, 1990). All clinicians were trained and supervised to
competence in the administration of the MINI for the current study.
2.2.4.2. Treatment satisfaction and acceptability. Consistent with
previous research (Titov et al., 2013a,b; Dear, Gandy et al., 2015;
Dear, Staples et al., 2015; Dear, Zou et al., 2015), treatment satis-
faction and acceptability were assessed at post-treatment via two
questions: (1) ‘Would you feel conﬁdent in recommending this
treatment to a friend?’ and (2) ‘Was it worth your time doing the
Course?’. Participants responded to these questions with a ‘Yes’ or
‘No’ response.
2.3. Interventions
All participants received access to either a DS-CBT course for
SAD, the Social Conﬁdence Course,  or a TD-CBT course, the Wellbe-
ing Course.  The Social Conﬁdence Course was  developed speciﬁcally
for this trial and the Wellbeing Course has been previously demon-
strated as clinically efﬁcacious in treating symptoms of anxiety and
depression (Titov et al., 2012a,b; Titov et al., 2013a,b; Titov et al.,
2014a,b). Consistent with the previous trials in this series of studies
(Dear, Gandy et al., 2015; Dear, Staples et al., 2015; Dear, Zou et al.,
2015; Titov, Dear, Staples, Bennett-Levy et al., 2015; Titov, Dear,
Staples, Terides et al., 2015), the two  courses comprised a similar
structure and similar amounts and forms of content to facilitate
comparisons. Both include ﬁve lessons delivered online over eight
weeks, lesson summaries and homework assignments for each les-
son, a similar number of detailed case stories, and a similar number
of additional resources targeting symptoms such as sleep prob-
lems and communication skills. Based on the content and previous
results (Titov, Dear, Staples, Bennett-Levy et al., 2015; Titov, Dear,
Staples, Terides et al., 2015), it is expected that reading the ﬁrst
four lessons of each course would provide an adequate therapeu-
tic dose. Each lesson is presented in a slide format combining text
and images, with approximately 60 slides per lesson and 50 words
per slide. Participants are instructed to read lessons in order over
8 weeks. Lessons 1, 2, 3, 4, and 5 are available at the beginning of
weeks 1, 2, 4, 5, and 7, respectively. This timetable provides partici-
pants with additional time for the most complex components of the
intervention; namely skills for managing cognitive and behavioural
symptoms.
Consistent with standard deﬁnitions (McEvoy et al., 2009) and
the other trials in this series of trials (Dear, Gandy et al., 2015;
Dear, Staples et al., 2015; Dear, Zou et al., 2015; Titov, Dear, Staples,
Bennett-Levy et al., 2015; Titov, Dear, Staples, Terides et al., 2015;
Fogliati, Dear et al., 2016), the TD-CBT intervention was the same
for all participants and was not designed to treat any speciﬁc
psychological disorder. Rather it aimed to present a broad range
of therapeutic information and skills relevant to the cognitive,
physical and behavioural symptoms of psychological distress gen-
erally. Reﬂecting this, the TD-CBT intervention did not mention
speciﬁc diagnoses and all vignettes, examples and case stories were
presented to cover a broad range of situations and types of psycho-
logical distress (e.g., excessive worry, low mood, social anxieties
and panic and strong physical sensations). In contrast, the DS-CBT
treatment was  speciﬁcally designed to target symptoms of SAD
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Table 2
Therapeutic content and skills included within the Transdiagnostic Wellbeing Course and Disorder-Speciﬁc Social Conﬁdence Course.
Lesson Transdiagnostic Wellbeing Course Disorder-Speciﬁc Social Conﬁdence Course
Lesson Content Primary Skills Taught Additional Resources Lesson Content Primary Skills Taught Additional Resources
1 Education about the general
prevalence and symptoms of anxiety
and low mood without mention of
speciﬁc disorders. Introduction of a
CBT model and explanation of the
functional relationship between
physical, thought and behavioural
symptoms in psychological distress.
Instructions for identifying their own
symptoms and how their symptoms
interact. Transdiagnostic vignettes and
examples of anxiety and low mood
symptoms provided.
– Symptom identiﬁcation
– Symptom formulation
– Sleep management
– What to do in a mental
health emergency
– Transdiagnostic Case
Stories
Education about the prevalence and symptoms
of SAD. Introduction of a CBT model and
explanation of the functional relationship
between physical, thought and behavioural
symptoms in SAD. Instructions for identifying
their own symptoms and how their symptoms
interact. SAD speciﬁc vignettes and examples
of SAD symptoms provided.
– Symptom identiﬁcation
–  Symptom formulation
– Sleep management
– What to do in a mental
health emergency
–  SAD Case Stories
2  Introduction to the basic principles of
cognitive therapy and importance of
managing thoughts to manage anxiety
and low mood. Instructions for
monitoring and challenging thoughts
related to anxiety and low mood.
Transdiagnostic vignettes and
examples of thoughts provided.
– Thought monitoring
– Thought challenging
– Structured problem
solving
– Worry Time
– Challenging beliefs
– Transdiagnostic Case
Stories
Introduction to the basic principles of cognitive
therapy and importance of managing thoughts
to  manage SAD. Instructions for monitoring
and challenging thoughts. SAD speciﬁc
vignettes and examples of thoughts provided.
– Thought monitoring
– Thought challenging
– Structured problem
solving
– Challenging beliefs
– SAD Case Stories
3  Introduction to the physical symptoms
of hyper-arousal and hypo-arousal and
their relationship to anxiety and low
mood. Instructions about controlling
physical symptoms using de-arousal
strategies such as controlled breathing
and scheduling pleasant activities.
Transdiagnostic vignettes and
examples of physical symptoms
provided.
– Controlled breathing
–  Pleasant activity
scheduling
– Risk Calculation, Coping
Calculation and Shifting
Attention
– 100 pleasant things to
do
– Transdiagnostic Case
Stories
Introduction to the physical symptoms of
hyper-arousal and their relationship to SAD.
Instructions about controlling physical
symptoms by using controlled breathing. SAD
speciﬁc vignettes and examples of physical
symptoms provided.
– Controlled breathing – Risk Calculation, Coping
Calculation and Shifting
Attention
– Communication Skills
– SAD Case Stories
4  Introduction to the behavioural
symptoms of anxiety and low mood.
Explanation of avoidance and safety
behaviours and their relationship to
ongoing distress. Instructions for
graded exposure for safely confronting
fears and increasing activity levels.
Transdiagnostic vignettes and
examples of graded exposure provided.
– Graded exposure
–  Behavioural activation
– Assertive
communication
– Transdiagnostic Case
Stories
Introduction to the behavioural symptoms of
SAD. Explanation of avoidance and safety
behaviours for SAD. Instructions for graded
exposure for safely confronting fears and
increasing social engagement. SAD speciﬁc
vignettes and examples of graded exposure
provided.
– Graded exposure – Assertive
communication
– SAD Case Stories
5  Information about the occurrence of
lapses and the process of recovery
from anxiety and low mood.
Information about the signs of relapse
and managing lapses. Instructions for
creating a relapse prevention plan.
Transdiagnostic vignettes and
examples of lapses and lapse
management provided.
– Relapse prevention – Transdiagnostic Case
Stories
Information about the occurrence of lapses and
the process of recovery from SAD. Information
about the signs of relapse and managing lapses.
Instructions for creating a relapse prevention
plan. SAD speciﬁc vignettes and examples of
lapses and lapse management provided.
– Relapse prevention – SAD Case Stories
Note. The transdiagnostic course was designed in such a way  that no speciﬁc anxiety or depressive disorder was  mentioned throughout the materials, vignettes, examples and case stories. The disorder speciﬁc course made
speciﬁc  mention of SAD and the materials, vignettes, examples and case stories all focussed on SAD.
3 nxiety
a
o
e
o
o
t
a
t
f
i
a
ﬁ
S
(
a
a
(
o
p
d
c
i
r
a
c
s
a
r
r
i
w
w
(
r
t
t
f
l
w
a
2
o
2
S
2
d
a
g
p
c
w
y
w
t
e
t
c
c
p
r6 B.F. Dear et al. / Journal of A
nd presented all therapeutic information and skills in the context
f SAD and reducing SAD symptoms. Consequently, all vignettes,
xamples and case stories focussed on SAD and the management
f associated symptoms and no speciﬁc mention of other diagnoses
r the broader application of therapeutic skills was made. The con-
ent and differences between the TD-CBT and DS-CBT interventions
re summarised in Table 2.
As with the other trials in this series of studies, participants in
he clinician-guided condition (CG-CBT) received weekly contact
rom a psychologist using telephone or a secure email messag-
ng system. Four accredited and nationally registered psychologists
nd one provisional psychologist provided treatment. Based on the
ndings of previous studies (Craske et al., 2009; Johnston, Titov,
pence, Andrews, & Dear, 2011) and to minimise therapist drift
Waller 2009), the nature of the contact was protocolised and key
ims included (1) reinforcing the main messages of each lesson, (2)
nswering questions, (3) reinforcing progress and skills practice,
4) problem solving skills usage, (5) normalising the challenges
f recovery, and (6) obtaining feedback about the participant’s
erception and engagement with the course. Each contact was
esigned to take ≤ 10 min, but more time was provided when
linically indicated. The psychologists received training in online
nterventions via the training program at the eCentreClinic and
eceived supervision from BFD and NT during weekly individual
nd group supervision sessions. Participants in the self-guided
ondition did not receive weekly contact, but their progress and
ymptoms were monitored throughout treatment by the clinicians
nd were able to contact the clinic if technical assistance was
equired or if they were experiencing a mental health crisis. A
esearch assistant provided technical support for all participants
n the trial.
All participants received an email at the start of the intervention
ith guidelines about the course and a recommended timetable for
orking through the materials. Consistent with previous research
Titov et al., 2013a,b; Titov et al., 2014a,b), all participants also
eceived automated emails at the beginning of each week to inform
hem about additional resources and to recommend activities for
hat week. All participants also received automatic emails that rein-
orced their progress, congratulated them on the completion of
essons, and reminded them about the availability of new materials
hen they had not viewed them within a week of them becoming
vailable.
.4. Statistical analyses
The same analytic approach was employed in this trial as in the
ther published trials in this series of studies (Dear, Gandy et al.,
015; Dear, Staples et al., 2015; Dear, Zou et al., 2015; Titov, Dear,
taples, Bennett-Levy et al., 2015; Titov, Dear, Staples, Terides et al.,
015). All analyses were conducted using SPSS version 21. Group
ifferences in demographic variables and diagnostic variables were
nalysed using binomial and multinomial logistic regression and
eneral linear models analyses. The alpha signiﬁcance level for the
reliminary analyses was adjusted from 0.05 to 0.01 as a partial
ontrol for the large number of analyses conducted. Participants
ho did not start the interventions were not included in any anal-
ses.
The generalised estimation equation (GEE) modelling technique
as employed to examine changes in symptom measures over
ime. GEE emphasizes the modelling of change in an average group
ffect over time while accounting for within-subject variance with
he speciﬁcation of a working correlation structure. Rather than
reating conditional interpretation with the use of individual inter-
epts or random slopes, as in traditional mixed linear models, the
rimary emphasis in GEE is to directly model the average group-
elated change over time (Hubbard et al., 2010). An exchangeable Disorders 42 (2016) 30–44
working correlation structure and maximum likelihood estimation
were selected, coupled with a robust error estimation for the pur-
poses of model parsimony, for all GEE analyses. All GEE  models also
speciﬁed a gamma  distribution with a log link response scale to
address positive skewness in the dependent variable distributions.
Importantly, in the GEE analyses, the model coefﬁcients represent
multiplicative change in the dependent variable from baseline;
these coefﬁcients result in a change factor (i.e., exp()), which can
be used to calculate the average percentage change of symptoms
from baseline. Consistent with the principles of intention-to-treat
analyses, separate GEE models utilising random intercepts were
employed to impute missing data. The same approach was used for
imputing missing binary diagnostic values. Speciﬁcally, probabil-
ity values were imputed based on an individual’s initial diagnostic
status combined with time by treatment condition estimates and
cases demonstrating higher cumulative probability than the base-
line value being imputed as having a diagnosis.
To maximise power and the interpretability of results, the two
Treatment Approaches and the two Support Formats were ana-
lysed separately; however, to ensure these analyses did not obscure
important patterns within the data, all higher order interactions
were explored ﬁrst. Following these initial explorations, a system-
atic series of analyses were employed to comprehensively compare
the two  treatment approaches (TD-CBT vs. DS-CBT) and the two
support formats (CG-CBT vs. SG-CBT). First, to explore efﬁcacy
across symptom domains, GEE analyses were conducted on the pri-
mary and secondary outcome variables from baseline to 24-month
follow-up focussed on the four symptom domains (i.e., depres-
sion, generalised anxiety, social anxiety and panic) among those
meeting MINI diagnostic criteria for the related disorder (i.e., MDD,
GAD, SAD and PD) at assessment. Second, to explore efﬁcacy in
terms of general psychological distress, disability and neuroticism,
GEE analyses were conducted on the tertiary outcomes from base-
line to 24-month follow-up using the overall sample data. Third,
for the binary outcome variable of diagnostic status, GEE analy-
ses were conducted using a binary scale and logit link function
implementing quasi-likelihood probability estimates at each time
point between groups. Fourth, to examine the overall cumulative
reduction in comorbid diagnoses, the average count of comorbid
diagnoses was analysed over time and between groups with a
negative binomial probability distribution and a log link function.
Finally, to explore acceptability and satisfaction, one-way factorial
ANOVAs and chi-square analyses were conducted on the lesson
completion and treatment satisfaction data. For comparison and
benchmarking purposes, Cohen’s d effect sizes and 95% conﬁdence
intervals were calculated for the within-group and between-group
effects based on the estimated marginal means derived from the
GEE models. The average percentage change across time was  also
calculated from the GEE analyses for each of the outcome variables
with 95% conﬁdence intervals. Importantly, to accurately reﬂect
percentage change, a constant of 10 was subtracted from K10 scores
when calculating percentage change scores.
3. Results
3.1. Preliminary analyses
3.1.1. Baseline differences
Demographic and diagnostic characteristics of the sample are
shown in Table 1. Speciﬁc details of participant ﬂow, treatment
attrition, lesson completion and questionnaire response are shown
in Fig. 1. There were no signiﬁcant differences between the TD-CBT
and DS-CBT groups or the CG-CBT and SG-CBT groups at baseline
(ps ≥ 0.05). There were no differences between participants com-
pleting and not completing the questionnaires at post-treatment,
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or any of the demographic variables reported in Table 1 or in base-
ine outcome measure scores (ps ≥ 0.05).
.1.2. Clinician time
There were signiﬁcant differences in clinician contact time
etween CG-CBT and SG-CBT groups (F1,217 = 280.99, p < 0.001). The
ean clinician time per participant in CG-CBT group was  36.54 min
SD = 22.16), which comprised answering and making calls (total
alls = 734; range = 0 to 21 calls; mean time = 23.39; SD = 22.01), as
ell as reading, sending and responding to secure emails (total
mails = 712; range = 0 to 29 emails; mean time = 13.15; SD = 9.62).
he mean total clinician time per participant for SG-CBT was
.64 min  (SD = 2.12), which comprised answering and making calls
total calls = 4; range = 0 to 2 calls; mean time = 0.07; SD = 0.49), as
ell as reading, sending and responding to secure emails (total
mails = 23; range = 0 to 3 emails; mean time = 0.56; SD = 2.02). This
ontact was focused on assessing and managing mental health
rises rather than providing treatment or course-related clinical
upport. No signiﬁcant differences were found between the TD-CBT
nd DS-CBT in the amount of clinician time required (F1,217 < 0.01,
 = 0.994).
.1.3. Preliminary test for higher order interactions
The GEE analyses revealed non-signiﬁcant treatment approach
y support format by Time interactions for all outcomes
MINI-SPIN: Wald’s 2 = 0.672, p = 0.995; GAD-7: Wald’s 2 = 3.45,
 = 0.485; PHQ-9: Wald’s 2 = 1.74, p = 0.782; PDSS-SR: Wald’s
2 = 4.24, p = 0.374; K10: Wald’s 2 = 5.03, p = 0.169; SDS: Wald’s
2 = 2.47, p = 0.649; NEO-FFI-N: Wald’s 2 = 4.64, p = 0.199).
.2. Transdiagnostic CBT (TD-CBT) versus disorder-speciﬁc CBT
DS-CBT)
The means, percentage reductions and effect sizes for the TD-
BT and DS-CBT groups are shown in Table 3.
.2.1. Outcomes across the diagnoses
.2.1.1. Social anxiety disorder. Among those meeting diagnostic
riteria for SAD (n = 206) the GEE analyses indicated a signiﬁcant
ffect for Time (MINI-SPIN: Wald’s 2 = 397.29, p < 0.001) but no
igniﬁcant Time by Treatment Approach interaction for social anx-
ety symptoms (MINI-SPIN: Wald’s 2 = 8.11, p = 0.087). Pairwise
omparisons indicated that participants improved from baseline
o post-treatment (p < 0.001), from post-treatment to 3-month
ollow-up (p = 0.002), 3-month to 12-month follow-up (p = 0.032),
ut not 12-month to 24-month follow-up (p = 0.250).
.2.1.2. Major depressive disorder. Among those meeting diagnos-
ic criteria for MDD  (n = 87) the GEE analyses indicated a signiﬁcant
ffect for Time (PHQ-9: Wald’s 2 = 246.31, p < 0.001) but no signiﬁ-
ant Time by Treatment Approach interaction effect for depressive
ymptoms (PHQ-9: Wald’s 2 = 7.99, p = 0.092). Pairwise compar-
sons indicated that participants improved similarly from baseline
o post-treatment (p < 0.001) and from post-treatment to 3-month
ollow-up (p = 0.002). No other signiﬁcant changes were observed
etween the other time points.
.2.1.3. Generalised anxiety disorder. Among those meeting diag-
ostic criteria for GAD (n = 102) the GEE analyses indicated a
igniﬁcant effect for Time (GAD-7: Wald’s 2 = 177.32, p < 0.001)
ut no signiﬁcant Time by Treatment Approach interaction for GAD
ymptoms (GAD-7: Wald’s 2 = 2.07, p = 0.723). Pairwise compar-
sons indicated that participants improved similarly from baseline
o post-treatment (p < 0.001) and no other signiﬁcant changes
etween the other time points. Disorders 42 (2016) 30–44 37
3.2.1.4. Panic disorder. Among those meeting diagnostic criteria
for PD (n = 61) the GEE analyses indicated a signiﬁcant effect
for Time (PDSS-SR: Wald’s 2 = 62.07, p < 0.001) but no signiﬁ-
cant Time by Treatment Approach interaction for panic symptoms
(PDSS-SR: Wald’s 2 = 7.96, p = 0.093). Pairwise comparisons indi-
cated that participants improved similarly from baseline to
post-treatment (p < 0.001) and from post-treatment to 3-month
follow-up (p = 0.002). No other signiﬁcant changes were observed
between the other time points.
3.2.2. Outcomes for general psychological distress, disability, and
neuroticism
Across the whole sample (n = 220) the GEE analyses indicated a
signiﬁcant effect for Time (K10: Wald’s 2 = 297.61, p < 0.001) but
no signiﬁcant Time by Treatment Approach interaction for general
psychological distress (K10: Wald’s 2 = 4.70, p = 0.195). Pairwise
comparisons indicated that participants improved similarly from
baseline to post-treatment (p < 0.001) and from post-treatment to
3-month follow-up (p < 0.001). No other signiﬁcant changes were
observed between the other time points.
Across the whole sample (n = 220) there was a signiﬁcant effect
for Time (SDS: Wald’s 2 = 280.36, p < 0.001) but no signiﬁcant
Time by Treatment Approach interaction for disability (SDS: Wald’s
2 = 1.40, p = 0.844). Pairwise comparisons indicated that par-
ticipants improved from baseline to post-treatment (p < 0.001),
post-treatment to 3-month follow-up (p < 0.001), 3-month to 12-
month follow-up (p = 0.048) and 12-month to 24-month follow-up
(p = 0.010).
Across the whole sample (n = 220) there was a signiﬁcant
effect for Time (NEO-FFI-N: Wald’s 2 = 205.49, p < 0.001) but
no signiﬁcant Time by Treatment Approach interaction for
neuroticism (NEO-FFI-N: Wald’s 2 = 4.00, p = 0.261). Pairwise com-
parisons indicated that participants improved from baseline to
post-treatment (p < 0.001), post-treatment to 3-month follow-up
(p < 0.001) and 3-month to 12-month follow-up (p = 0.006).
3.2.3. Changes in diagnostic status
The numbers and changes in the proportion of participants
meeting formal diagnostic criteria at initial assessment and 3-
month follow-up are shown in Table 5. The GEE  analyses of
diagnoses revealed a signiﬁcant effect for Time across the diag-
noses (SAD: Wald’s 2 = 89.01, p < 0.001; MDE; Wald’s 2 = 68.50,
p < 0.001; GAD: Wald’s 2 = 39.84, p < 0.001; PD: Wald’s 2 = 38.07,
p < 0.001). No signiﬁcant Time by Treatment Approach interactions
were observed for any diagnoses (SAD: Wald’s 2 = 0.22, p = 0.635;
MDE: Wald’s 2 = 0.88, p = 0.348; GAD: Wald’s 2 = 0.27, p = 0.602;
PD: Wald’s 2 = 0.25, p = 0.612) indicating that the proportion
of participants meeting diagnostic criteria signiﬁcantly reduced
across time irrespective of Treatment Approach.
The GEE analyses focusing on average comorbid diagnoses
revealed a signiﬁcant Time effect (Wald’s 2 = 197.76, p < 0.001)
but no Time by Treatment Approach interaction (Wald’s 2
= 0.84, p = 0.358). These analyses indicated signiﬁcant reductions in
comorbid diagnoses amongst both the TD-CBT and DS-CBT groups
over time.
3.2.4. Treatment completion and satisfaction rates
There was no signiﬁcant difference in the number of lessons read
by the TD-CBT (M = 4.31; SD = 1.13) and DS-CBT groups (M = 4.37;
SD = 1.13) at post-treatment (F1,218 = 0.15, p = 0.696). Of the partic-
ipants that completed the evaluation questions at post-treatment,
94% (80/85) of the TD-CBT group and 95% (92/97) of the DS-CBT
group, reported they would recommend the course to others. More-
over, 94% (79/84) of the TD-CBT group and 97% (94/97) of the
DS-CBT group reported participating in the course was worth their
time. There were no signiﬁcant differences between the groups in
38
 
B.F.
 D
ear
 et
 al.
 /
 Journal
 of
 A
nxiety
 D
isorders
 42
 (2016)
 30–44
Table 3
Means, percentage change and effect sizes: transdiagnostic (TD-CBT) versus disorder speciﬁc (DS-CBT).
Estimated  Marginal  Means %  Change  from  baseline Within  Group  Cohen’s  d  from  baseline Between  Group  Cohen’s  d
Baseline  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth
PRINCIPAL  OUTCOME
Social  Anxiety  Symptoms a
DS-CBT  (n  =  106)  9.53  (2.10)
[9.14, 9.94]
6.18  (3.17)
[5.60,  6.81]
5.52  (2.83)
[5.01,  6.08]
5.62  (2.79)
[5.11,  6.18]
5.37  (2.98)
[4.84,  5.97]
35%  [28%,  41%]  42%  [36%,  47%]  41%  [35%,  46%]  44%  [37%,  49%]  1.25  [0.95,
1.54]
1.61  [1.29,
1.91]
1.58  [1.27,
1.89]
1.61  [1.30,
1.92]
−0.06
[−0.33,
0.22]
−0.15
[−0.43,
0.12]
0.18  [−0.10,
0.45]
0.13  [−0.14,
0.41]
TD-CBT (n  =  100) 9.36  (2.10)
[8.95, 9.79]
6.36  (3.20)
[5.75,  7.02]
5.97  (3.00)
[5.40,  6.59]
5.12  (2.90)
[4.58,  5.71]
4.97  (3.00)
[4.42,  5.59]
32%  [25%,  39%] 36%  [30%,  42%]  45%  [39%,  51%]  47%  [40%,  53%]  1.11  [0.81,
1.40]
1.31  [1.00,
1.61]
1.67  [1.35,
1.99]
1.70  [1.37,
2.01]
SECONDARY OUTCOMES
Depression  Symptoms b
DS-CBT  (n  =  49)  13.80  (3.71)
[12.80,
14.87]
8.40  (4.83)
[7.16,  9.87]
6.74  (4.76)
[5.53,  8.22]
7.69  (4.83)
[6.46,  9.16]
7.29  (4.62)
[6.11,  8.70]
39%  [28%,  48%]  51%  [40%,  60%]  44%  [34%,  53%]  47%  [37%,  56%]  1.25  [0.81,
1.68]
1.65  [1.18,
2.10]
1.42  [0.97,
1.85]
1.55  [1.09,
1.99]
0.09  [−0.34,
0.51]
−0.22
[−0.64,
0.21]
0.10  [−0.32,
0.53]
−0.20
[−0.62,
0.23]
TD-CBT (n  =  38)  14.53  (4.13)
[13.27
15.90]
8.00  (4.25)
[6.76,  9.46]
7.67  (3.64)
[6.60,  8.92]
7.24  (3.70)
[6.15,  8.52]
8.21  (4.56)
[6.8,8  9.80]
45%  [35%,  53%]  47%  [39%,  55%]  50%  [41%,  58%]  43%  [33%,  53%]  1.56  [1.03,
2.05]
1.76  [1.22,
2.27]
1.86  [1.30,
2.38]
1.45  [0.93,
1.94]
Generalised Anxiety  Symptoms
c
DS-CBT  (n  =  49) 11.47  (4.97)
[10.16,
12.95]
7.02 (5.32)
[5.67,  8.69]
6.35  (5.39)
[5.01,  8.06]
5.33  (4.55)
[4.20,  6.78]
5.54  (4.62)
[4.38,  6.99]
39%  [24%,  51%] 45%  [30%,  56%]  54%  [41%,  63%]  52%  [39%,  62%]  0.86  [0.44,
1.27]
0.99  [0.56,
1.40]
1.29  [0.84,
1.71]
1.24  [0.79,
1.66]
−0.22
[−0.60,
0.18]
−0.18
[−0.57,
0.21]
−0.32
[−0.71,
0.07]
−0.06
[−0.45,
0.33]
TD-CBT (n  =  53) 12.70  (4.30)
[11.60,
13.91]
8.09  (4.59)
[6.95,  9.43]
7.25  (4.66)
[6.10,  8.62]
6.68  (3.79)
[5.74,  7.77]
5.76  (3.86)
[4.81,  6.88]
36%  [26%,  45%]  43%  [32%,  52%]  47%  [39%,  55%]  55%  [46%,  62%]  1.04  [0.62,
1.43]
1.22  [0.79,
1.62]
1.49  [1.04,
1.90]
1.70  [1.24,
2.13]
Panic Symptoms d
DS-CBT  (n  =  33)  10.52  (5.57)
[8.78, 12.59]
5.94  (4.02)
[4.71,  7.47]
4.75  (4.19)
[3.52,  6.41]
5.15  (4.19)
[3.90,  6.78]
5.75  (5.69)
[4.10,  8.05]
44%  [29%,  55%]  55%  [39%,  67%]  51%  [35%,  63%]  45%  [23%,  61%]  0.94  [0.42,
1.44]
1.17  [0.64,
1.68]
1.09  [0.56,
1.59]
0.85  [0.33,
1.34]
−0.76
[−1.27,
−0.22]
−0.57
[−1.07,
−0.05]
−0.41
[−0.91,
0.10]
−0.10
[−0.60,
0.40]TD-CBT (n  =  28)  13.29  (5.66)
[11.34,
15.57]
9.99  (6.61)
[7.82,  1277]
7.95  (6.98)
[5.74,  10.99]
7.23  (5.93)
[5.34,  9.80]
6.39  (7.04)
[4.25,  9.62]
25%  [4%,  41%]  40%  [17%,  57%]  46%  [26%,  60%]  52%  [28%,  68%]  0.54  [0.0,
1.06]
0.84  [0.28,
1.37]
1.05  [0.47,
1.59]
1.08  [0.51,
1.62]
TERTIARY OUTCOMES
Disability  and  Functioning
(SDS)
DS-CBT  (n  =  115)  13.25  (7.29)
[11.99,
14.64]
8.95  (7.61)
[7.66,  10.46]
7.44  (6.76)
[6.31,  8.78]
6.99  (6.22)
[5.95,  8.22]
5.90  (6.22)
[4.86,  7.16]
32%  [21%,  42%]  44%  [34%,  52%]  47%  [38%,  55%]  56%  [46%,  63%]  0.58  [0.31,
0.84]
0.83  [0.55,
1.09]
0.92  [0.65,
1.19]
1.08  [0.80,
1.36]
−0.15
[−0.42,
0.11]
−0.20
[−0.46,
0.07]
−0.11
[−0.37,
0.16]
−0.13
[−0.40,
0.13]
TD-CBT (n  =  105)  14.21  (7.89)
[12.77,
15.81]
10.11  (7.79)
[8.72, 11.73]
8.85  (7.38)
[7.54,  10.39]
7.71  (6.87)
[6.50,  9.14]
6.74  (6.46)
[5.61,  8.10]
29  [17%,  39%]  38  [27%,  47%]  46  [36%,  54%]  53 [43%,  61%]  0.52  [0.25,
0.80]
0.70  [.42,
0.98]
0.88  [0.59,
1.16]
1.04  [0.74,
1.32]
Psychological Distress  (K−10) e
DS-CBT  (n  =  115)  24.85  (7.43)
[23.53,
26.25]
20.23  (7.03)
[18.99,
21.56]
18.31  (6.08)
[17.23,
19.45]
18.62  (6.43)
[17.48,
19.84]
–  29%  [20%,  39%]  36%  [27%,  44%]  44%  [37%,  52%]  – 0.64  [0.37,
0.90]
0.96  [0.69,
1.23]
0.90  [0.62,
1.16]
– −0.04
[−0.30,
0.23]
−0.19
[−0.45,
0.08]
0.06  [−0.21,
0.32]
–
TD-CBT (n  =  105)  24.90  (7.65)
[23.47,
26.40]
20.51  (7.45)
[19.14,
21.99]
19.53  (6.80)
[18.27,
20.87]
18.28  (5.84)
[17.20,
19.43]
–  31%  [22%,  39%]  44%  [36%,  51%]  42%  [34%,  50%]  – 0.58  [0.30,
0.86]
0.74  [0.46,
1.02]
0.97  [0.68,
1.26]
–
Neuroticism (NEO-FFI-N)
DS-CBT  (n  =  115)  32.73  (6.97)
[31.48,
34.04]
29.19  (7.72)
[27.80,
30.64]
26.83  (7.40)
[25.52,
28.20]
26.47  (7.83)
[25.09,
27.94]
–  11%  [6%,  15%]  18%  [14%,  22%]  19%  [15%,  23%]  – 0.48  [0.22,
0.74]
0.82  [0.55,
1.09]
0.84  [0.57,
1.11]
– −0.03
[−0.29,
0.24]
−0.10
[−0.36,
0.16]
0.07  [−0.19,
0.34]
–
TD-CBT (n  =  105) 32.21  (6.87)
[30.92,
33.56]
29.41  (7.48)
[28.01,
30.88]
27.57  (7.38)
[26.20,
29.00]
25.92  (6.87)
[24.64,
27.26]
–  9%  [4%,  13%]  14%  [10%,  19%]  20%  [15%,  24%]  – 0.39  [0.12,
0.66]
0.65  [0.37,
0.93]
0.92  [0.63,
1.20]
–
Note. Standard deviations are shown in rounded parentheses for the means and 95% conﬁdence intervals are shown in square parentheses. Percentage reductions derived from the model change factor (i.e., 1 − exp()) in the
model.
Social  anxiety, depression, generalised anxiety, and panic symptoms were measured with the MINI-SPIN, PHQ-9, GAD-7, and PDSS-SR, respectively.
a Analyses use the data of participants meeting diagnostic criteria for Social Anxiety Disorder at assessment.
b Analyses use the data of participants meeting diagnostic criteria for Major Depressive Disorder at assessment.
c Analyses use the data of participants meeting diagnostic criteria for Generalised Anxiety Disorder at assessment.
d Analyses use the data of participants meeting diagnostic criteria for Panic Disorder at assessment.
e To accurately reﬂect percentage change, a constant of 10 was subtracted from K10 scores when calculating percentage change scores.
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he proportions of participants who reported they would recom-
end the course or reporting ﬁnding the course was  worth their
ime (2 range = 0.05 to 0.87; p range = 0.284 to 0.541).
.3. Clinician-Guided CBT (CG-CBT) versus self-guided CBT
DS-CBT)
The means, standard deviations and effect sizes for the CG-CBT
nd SG-CBT groups are shown in Table 4.
.3.1. Outcomes across the diagnoses
.3.1.1. Social anxiety disorder. Among those meeting diagnostic
riteria for SAD (n = 206) the GEE analyses indicated a signiﬁ-
ant effect for Time (MINI-SPIN: Wald’s 2 = 406.78, p < 0.001) and
 signiﬁcant Time by Treatment Approach interaction for social
nxiety symptoms (MINI-SPIN: Wald’s 2 = 12.13, p = 0.016). Pair-
ise comparisons indicated that both groups improved similarly
rom baseline to post-treatment (p < 0.001) and that the CG-CBT
roup further improved from post-treatment to 3-month follow-
p (p < 0.001) where the SG-CBT group improved signiﬁcantly
etween 3-month and 12-month follow-up (p < 0.001). The only
igniﬁcant difference between the groups was found at 3-month
ollow-up (p = 0.003), where the CG-CBT group reported slightly
ewer symptoms than the SG-CBT group. No other signiﬁcant dif-
erences were found.
.3.1.2. Major depressive disorder. Among those meeting diagnos-
ic criteria for MDD  (n = 87) the GEE analyses indicated a signiﬁcant
ffect for Time (PHQ-9: Wald’s 2 = 238.85, p < 0.001) but no signif-
cant Time by Treatment Approach interaction effect for depressive
ymptoms (PHQ-9: Wald’s 2 = 0.370, p = 0.985). Pairwise compar-
sons indicated that participants improved similarly from baseline
o post-treatment (p < 0.001) and from post-treatment to 3-month
ollow-up (p = 0.002). There were no other signiﬁcant changes
etween the other time points.
.3.1.3. Generalised anxiety disorder. Among those meeting diag-
ostic criteria for GAD (n = 102) the GEE analyses indicated a
igniﬁcant effect for Time (GAD-7: Wald’s 2 = 200.74, p < 0.001)
ut no signiﬁcant Time by Treatment Approach interaction for GAD
ymptoms (GAD-7: Wald’s 2 = 3.81, p = 0.432). Pairwise compar-
sons indicated that participants improved similarly from baseline
o post-treatment (p < 0.001) and from 3-month to 12-month
ollow-up (p = 0.042). There were no other signiﬁcant changes
etween the other time points.
.3.1.4. Panic disorder. Among those meeting diagnostic criteria
or PD (n = 61) the GEE analyses indicated a signiﬁcant effect
or Time (PDSS-SR: Wald’s 2 = 60.57, p < 0.001) but no signiﬁ-
ant Time by Treatment Approach interaction for panic symptoms
PDSS-SR: Wald’s 2 = 2.69, p = 0.611). Pairwise comparisons
ndicated that participants improved similarly from baseline to
ost-treatment (p < 0.001) and from post-treatment to 3-month
ollow-up (p = 0.001). There were no other signiﬁcant changes
etween the other time points.
.3.2. Outcomes for general psychological distress, disability, and
euroticism
Across the whole sample (n = 220) the GEE analyses indicated a
igniﬁcant effect for Time (K10: Wald’s 2 = 296.38, p < 0.001) but
o signiﬁcant Time by Treatment Approach interaction for general
sychological distress (K10: Wald’s 2 = 4.17, p = 0.243). Pairwise
omparisons indicated that participants improved from baseline
o post-treatment (p < 0.001) and from post-treatment to 3-month
ollow-up (p < 0.002). Disorders 42 (2016) 30–44 39
Across the whole sample (n = 220) there was a signiﬁcant effect
for Time (SDS: Wald’s 2 = 280.79, p < 0.001) but no signiﬁcant
Time by Treatment Approach interaction for disability (SDS: Wald’s
2 = 6.78, p = 0.147). Pairwise comparisons indicated that par-
ticipants improved from baseline to post-treatment (p < 0.001),
post-treatment to 3-month follow-up (p < 0.001), 3-month to 12-
month follow-up (p = 0.049) and 12-month to 24-month follow-up
(p = 0.009).
Across the whole sample (n = 220) there was a signiﬁcant
effect for Time (NEO-FFI-N: Wald’s 2 = 210.72, p < 0.001) but
no signiﬁcant Time by Treatment Approach interaction for
neuroticism (NEO-FFI-N: Wald’s 2 = 2.54, p = 0.467). Pairwise
comparisons indicated that participants improved from base-
line to post-treatment and from post-treatment to 3-month
follow-up (ps < 0.001). Pairwise comparisons indicated that par-
ticipants improved from baseline to post-treatment (p < 0.001),
post-treatment to 3-month follow-up (p < 0.001) and 3-month to
12-month follow-up (p = 0.008).
3.3.3. Changes in diagnostic status
The numbers and changes in the proportion of participants
meeting formal diagnostic criteria at initial assessment and 3-
month follow-up are shown in Table 5. The GEE  analyses of
diagnoses revealed a signiﬁcant effect for Time across the diag-
noses (SAD: Wald’s 2 = 89.14, p < 0.001; MDE; Wald’s 2 = 68.64,
p < 0.001; GAD: Wald’s 2 = 39.33, p < 0.001; PD: Wald’s 2 = 38.58,
p < 0.001). No signiﬁcant Time by Support Format interactions were
observed for any diagnoses (SAD: Wald’s 2 = 1.63, p = 0.202; MDE:
Wald’s 2 = 0.06, p = 0.795; GAD: Wald’s 2 = 1.21, p = 0.269; PD:
Wald’s 2 = 2.54, p = 0.111) indicating that the proportion of partic-
ipants meeting diagnostic criteria signiﬁcantly reduced across time
irrespective of Support Format.
The GEE analyses focused on average comorbid diagnoses
revealed a signiﬁcant Time effect (Wald’s 2 = 197.65, p < 0.001) but
no Time by Support Format interaction (Wald’s 2 = 1.24, p = 0.265).
These analyses indicated signiﬁcant reductions in comorbid diag-
noses amongst both the CG-CBT and SG-CBT groups over time.
3.3.4. Treatment completion and satisfaction rates
There was no difference in the number of lessons completed by
the CG-CBT (M = 4.39; SD = 1.09) and SG-CBT (M = 4.30; SD = 1.17)
groups at post-treatment (F1,218 = 0.40, p = 0.526). Of the partici-
pants who completed the evaluation questions at post-treatment,
96% (94/98) of the CG-CBT group, and 93% (78/84) of the SG-CBT
group, reported they would recommend the course to others. Further,
96% (94/98) of the CG-CBT group and 95% (79/83) of the SG-CBT
group reported the course was  worth their time. There were no
signiﬁcant differences in the proportions of participants willing to
recommend the course or ﬁnding the course was worth their time
(2 range: 0.06–.82; p = 0.366 to 0.810).
4. Discussion
The present study is one of a series of RCTs comparing the
efﬁcacy and acceptability of transdiagnostic and disorder-speciﬁc
internet-delivered CBT when provided with and without clinician
contact (Dear, Gandy et al., 2015; Dear, Staples et al., 2015; Dear,
Zou et al., 2015; Titov, Dear, Staples, Bennett-Levy et al., 2015; Titov,
Dear, Staples, Terides et al., 2015; Fogliati, Dear et al., 2016). In the
present trial, it was hypothesised that both TD-CBT and DS-CBT
would result in signiﬁcant improvements on principal symptoms of
SAD, but that TD-CBT would be associated with superior improve-
ments to DS-CBT on comorbid symptoms of depression, general
anxiety and panic at each time point. It was  also hypothesised that
CG-CBT would be superior to SG-CBT on both principal and comor-
bid symptoms at each time point. These hypotheses were only
40
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Table 4
Means, percentage change and effect sizes: clinician-guided (CG-CBT) versus self-guided (SG-CBT).
Estimated  Marginal  Means  %  Change  from  baseline  Within  Group  Cohen’s  d  from  baseline  Between  Group  Cohen’s  d
Baseline  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth  Post  3mth  12mth  24mth
PRINCIPAL  OUTCOME
Social  Anxiety  Symptoms
a
CG-CBT  (n  =  107)  9.44  (1.97)
[9.07,  9.83]
5.96  (3.10)
[5.40,  6.57]
5.16  (2.79)
[4.66,  5.73]
5.25  (2.79)
[4.74,  5.81]
5.08  (3.21)
[4.51,  5.72]
37%  [30%,
43%]
45% [39%,
51%]
44% [38%,
50%]
46%  [39%,
52%]
1.34 [1.04,
1.63]
1.77 [1.45,
2.08]
1.73  [1.41,
2.04]
1.64 [1.32,
1.94]
−0.20
[−0.47,
0.07]
−0.42
[−0.69,
−0.14]
−0.10
[−0.37,
0.18]
−0.07
[−0.34,
0.21]SG-CBT (n  =  99) 9.46  (2.29)
[9.02,  9.91]
6.60  (3.28)
[5.98,  7.28]
6.36  (2.98)
[5.80,  6.96]
5.52  (2.89)
[4.98,  6.11]
5.28  (2.79)
[4.76,  5.85]
30%  [23%,
37%]
33% [26%,
39%]
42% [35%,
47%]
44%  [38%,
50%]
1.01 [.71,
1.30]
1.17 [.86,
1.46]
1.51  [1.19,
1.82]
1.64 [1.31,
1.95]
SECONDARY OUTCOMES
Depression  Symptoms b
CG-CBT  (n  =  44)  14.61  (3.85)
[13.52,
15.80]
8.53 (4.51)
[7.30,  9.98]
7.29  (4.18)
[6.15,  8.64]
7.66  (4.97)
[6.33,  9.28]
7.78  (4.71)
[6.51,  9.31]
42%  [32%,
50%]
50%  [41%,
58%]
48% [36%,
57%]
47%  [36%,
55%]
1.45 [0.97,
1.91]
1.82 [1.31,
2.30]
1.56  [1.07,
2.03]
1.59 [1.10,
2.05]
0.14  [−0.29,
0.56]
0.06  [−0.36,
0.48]
0.08 [−0.34,
0.50]
0.04 [−0.38,
0.46]
SG-CBT (n  =  43)  13.61  (3.87)
[12.49,
14.82]
7.91 (4.59)
[6.65,  9.42],
7.01  (4.46)
[5.79,  8.48]
7.32  (3.61)
[6.32,  8.49]
7.60  (4.52)
[6.37,  9.07]
42%  [31%,
51%]
48% [38%,
57%]
46% [38%,
54%]
44%  [33%,
53%]
1.34 [0.86,
1.80]
1.58 [1.08,
2.05]
1.68  [1.17,
2.16]
1.43 [0.94,
1.89]
Generalised Anxiety
Symptoms c
CG-CBT  (n  =  58) 12.14  (4.87)
[10.95,
13.46]
7.44 (5.18)
[6.23,  8.89]
6.32  (4.80)
[5.20,  7.68]
6.15  (4.87)
[5.02,  7.55]
5.42  (4.34)
[4.41,  6.67]
39%  [27%,
49%]
48% [37%,
57%]
49% [38%,
59%]
55%  45%,
64%]
0.93 [0.55,
1.31]
1.20  [0.80,
1.59]
1.23  [.83,
1.62]
1.46 [1.04,
1.86]
−0.06
[−0.45,
0.33]
−0.23
[−0.62,
0.16]
0.07  [−0.33,
0.46]
−0.13
[−0.52,
0.27]
SG-CBT (n  =  44) 12.07  (4.38)
[10.84,
13.44]
7.75 (4.78)
[6.45,  9.31]
7.48  (5.31)
[6.07,  9.21]
5.87  (3.12)
[5.01,  6.87]
5.95  (4.05)
[4.88,  7.27]
36%  [23%,
47%]
38% [24%,
50%]
51% [43%,
58%]
51%  [40%,
60%]
0.94 [0.49,
1.37]
0.94 [0.49,
1.37]
1.63  [1.13,
2.10]
1.45 [.97,
1.91]
Panic Symptoms d
CG-CBT  (n  =  31)  12.13  (5.57)
[10.18,
14.45]
7.30 (5.57)
[5.48,  9.72]
5.54  (6.07)
[3.86,  7.94]
5.45  (5.12)
[3.90,  7.63]
5.41  (6.18)
[3.54,  8.28]
40%  [20%,
55%]
54% [35%,
68%]
55% [37%,
68%]
55%  [32%,
71%]
0.87 [0.34,
1.38]
1.13 [0.58,
1.65]
1.25  [0.69,
1.78]
1.14 [0.59,
1.66]
−0.18
[−0.68,
0.33]
−0.24
[−0.74,
0.27]
−0.26
[−0.76,
0.25]
−0.20
[−0.71,
0.30]
SG-CBT (n  =  30)  11.43  (5.92)
[9.63, 13.58]
8.32  (5.86)
[6.57,  10.53]
6.92  (5.59)
[5.08,  9.42]
6.78  (5.09)
[5.20,  8.83]
6.70  (6.41)
[4.83,  9.28]
27%  [8%,
43%]
40%  [18%,
56%]
41% [23%,
55%]
41%  [19%,
58%]
0.53 [0.01,
1.04]
0.78 [0.25,
1.30]
0.84  [0.30,
1.36]
0.77 [0.23,
1.28]
TERTIARY OUTCOMES
Disability  and  Functioning
(SDS)
CG-CBT  (n  =  112)  13.50  (7.51)
12.18,
14.96]
9.69 (7.83)
[8.35,  11.25]
7.54  (6.67)
[6.39,  8.89]
6.92  (6.56)
[5.80,  8.25]
6.60  (6.88)
[5.44,  8.01]
28%  [17%,
38%]
44% [34%,
53%]
49% [39%,
57%]
51%  [41%,
60%]
0.50  [0.23,
0.76]
0.84 [0.56,
1.11]
0.93  [0.65,
1.21]
0.96 [0.68,
1.23]
0.05  [−0.22,
0.31]
−0.17
[−0.43,
0.10]
−0.13
[−0.39,
0.13]
0.10  [−0.17,
0.36]
SG-CBT (n  =  108)  13.93  (7.69)
12.55,
15.45]
9.31 (7.69)
[7.96,  10.89]
8.72  (7.38)
[7.42,  10.23]
7.77  (6.44)
[6.64,  9.10]
5.98  (5.72)
[4.99,  7.17]
33%  [22%,
43%]
37% [27%,
47%]
44% [35%,
52%]
57%  [49%,
64%]
0.60  [0.33,
0.87]
.69 [.41,
0.96]
0.87  [0.59,
1.14]
1.17  [0.88,
1.46]
Psychological Distress
(K−10) e
CG-CBT  (n  =  112)  25.50  (8.15)
[24.04,
27.05]
20.95 (7.30)
[19.64,
22.34]
18.76 (6.56)
[17.57,
20.02]
18.79 (6.77)
[17.58,
20.08]
– 31%  [22%,
41%]
37% [28%,
45%]
45% [35%,
50%]
– 0.59  [0.32,
0.85]
0.91 [0.63,
1.18]
0.90 [0.62,
1.17]
– 0.16  [−0.10,
0.43]
−0.04
[−0.30,
0.22]
0.11 [−0.15,
0.38]
–
SG-CBT (n  =  108) 24.22  (6.75)
[22.98,
25.54]
19.77 (7.17)
[18.46,
21.16]
19.02  (6.34)
[17.87,
20.25]
18.12 (5.04)
[17.13,
19.18]
– 29%  [20%,
38%]
43% [35%,
51%]
43% [35%,
51%]
– 0.64  [0.36,
0.91]
0.79 [0.51,
1.07]
1.02  [0.74,
1.30]
–
Neuroticism (NEO-FFI-N)
CG-CBT  (n  =  112)  32.87  (6.98)
[31.60,
34.19]
30.18 (7.62)
[28.78,
31.64]
27.62 (7.51)
[26.30,
29.01]
26.51 (7.09)
25.12,
27.98]
– 8%  [4%,  12%]  16%  [12%,
20%]
19% [15%,
24%]
– 0.37  [.10,
0.63]
0.72 [0.45,
0.99]
0.90 [0.63,
1.18]
– 0.24  [−0.03,
0.50]
0.12  [−0.14,
0.39]
0.08  [−0.18,
0.35]
–
SG-CBT (n  =  108)  32.08  (6.86)
[30.81,
33.41]
28.37 (7.59)
[27.00,
29.81
26.72 (7.17)
[25.37,
28.14]
25.90  (7.59)
24.62,
27.24]
– 12%  [7%,
16%]
17% [12%,
21%]
19% [15%,
23%]
– 0.51  [.24,
0.78]
0.76 [0.48,
1.04]
0.85  [0.57,
1.13]
–
Note. Standard deviations are shown in rounded parentheses for the means and 95% conﬁdence intervals are shown in square parentheses. Percentage reductions derived from the model change factor (i.e., 1 − exp()) in the
model.
Social  anxiety, depression, generalised anxiety, and panic symptoms were measured with the MINI-SPIN, PHQ-9, GAD-7, and PDSS-SR, respectively.
a Analyses use the data of participants meeting diagnostic criteria for Social Anxiety Disorder at assessment.
b Analyses use the data of participants meeting diagnostic criteria for Major Depressive Disorder at assessment.
c Analyses use the data of participants meeting diagnostic criteria for Generalised Anxiety Disorder at assessment.
d Analyses use the data of participants meeting diagnostic criteria for Panic Disorder at assessment.
e To accurately reﬂect percentage change, a constant of 10 was subtracted from K10 scores when calculating percentage change scores.
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Table  5
Proportions meeting diagnostic criteria over time for each of the groups.
TD-CBT versus DS-CBT CG-CBT versus SG-CBT
Baseline 3mth % Change from Baseline Baseline 3mth % Change from Baseline
TD-CBT DS-CBT TD-CBT DS-CBT TD-CBT DS-CBT CG-CBT SG-CBT CG-CBT SG-CBT CG-CBT SG-CBT
DIAGNOSIS
Social Anxiety
Disorder
95%
[89%,98%]
92%
[86%,96%]
53%
[44%,63%]
47%
[38%,56%]
56%
[46%,66%]
51%
[41%,61%]
96%
[90%,98%]
92%
[85%,96%]
49%
[40%,58%]
51%
[42%,60%]
51%
[42%,61%]
56%
[45%,66%]
Generalised
Anxiety Disorder
50%
[41%,60%]
43%
[34%,52%]
24%
[16%,34%]
15%
[9%,24%]
53%
[32%,69%]
64%
[43%,78%]
52%
[43%,61%]
41%
[32%,50%]
19%
[12%,29%]
19%
[12%,29%]
63%
[44%,76%]
52%
[29%,70%]
Major Depressive
Disorder
36%
[28%,46%]
43%
[34%,52%]
7%
[3%,13%]
5%
[2%,11%]
82%
[63%,91%]
88%
[74%,94%]
39%
[31%,49%]
40%
[31%,49%]
6%
[3%,13%]
6%
[3%,12%]
84%
[68%,92%]
86%
[70%,94%]
Panic Disorder 27%
[19%,36%]
29%
[21%,38%]
11%
[7%,19%]
9%
[5%,16%]
32%
[17%,59%]
39%
[23%,64%]
28%
[20%,37%]
28%
[20%,37%]
7%
[4%,14%]
13%
[8%,21%]
26%
[13%,49%]
47%
[28%,75%]
COMORBID
DIAGNOSES
Average 2.08 2.06 0.86 0.75 59%
[50%,66%]
64%
[56%,70%]
2.14 2.00 0.77 0.83 64%
[56%,71%]
58%
[50%,66%]
Frequencya
0 5%
[2%,11%]
3%
[1%,8%]
41%
[32%,51%]
45%
[36%,54%]
– – 3%
[1%,8%]
6%
[3%,12%]
46%
[37%,55%]
41%
[32%,50%]
– –
1  46%
[36%,55%]
37%
[28%,46%]
37%
[28%,47%]
39%
[31%,48%]
– – 44%
[35%,53%]
38%
[29%,47%]
38%
[29%,47%]
39%
[30%,48%]
– –
2  31%
[23%,41%]
39%
[31%,48%]
18%
[12%,27%]
12%
[7%,20%]
– – 34%
[26%,43%]
37%
[28%,47%]
13%
[8%,20%]
18%
[12%,26%]
– –
3  13%
[8%,21%]
17%
[11%,24%]
3%
[1%,8%]
3%
[1%,8%]
– – 13%
[8%,21%]
17%
[11%,25%]
4%
[0%,9%]
2%
[1%,7%]
– –
N ates o
ary log
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sote: 95% conﬁdence intervals of estimates are shown in parentheses both for estim
a The frequency of comorbid diagnoses over time was estimated employing bin
ather  than simple raw counts.
artially supported. All conditions resulted in signiﬁcant improve-
ents across the outcome measures and these corresponded to
igniﬁcant reductions in the proportions of participants meeting
iagnostic criteria. No marked or consistent differences were found
etween participants who received TD-CBT and DC-CBT or CG-CBT
nd SG-CBT either in terms of symptom scores or changes in diag-
ostic status. Treatment completion, as indicated by the proportion
f participants across treatments groups who read four of the ﬁve
essons, was high amongst all groups, as was satisfaction with the
nterventions.
In the current trial TD-CBT and DS-CBT as well as CG-CBT and
G-CBT were all associated with similar levels of acceptability and
eductions in symptoms of SAD and other common comorbid dis-
rders. The magnitude of reductions in social anxiety symptoms
Cohen’s d ≥ 1.01; avg. reduction ≥ 30%) in the current trial were
arge across the conditions and consistent with those reported in
ace-to-face treatments (Butler et al., 2006; Stewart & Chambless
009; Cuijpers et al., 2014) and internet-delivered treatments for
AD (Andrews, Cuijpers, Craske, McEvoy, & Titov, 2010). There
as also evidence of large reductions in symptoms of comorbid
ajor depressive disorder (Cohen’s d ≥ 1.25; avg. reduction ≥ 39%)
nd generalised anxiety disorder (Cohen’s d ≥ 0.86; avg. reduc-
ion ≥ 36%), and moderate-to-large improvements in symptoms of
anic disorder (Cohen’s d ≥ 0.53; avg. reduction ≥ 25%). It is also
mportant to note that signiﬁcant reductions in general psycho-
ogical distress (Cohen’s d ≥ 0.58; avg. reduction ≥ 18%), disability
Cohen’s d ≥ 0.50; avg. reduction ≥ 28%) and neuroticism (Cohen’s
 ≥ 0.37; avg. reduction ≥ 8%) were also observed across all condi-
ions. Signiﬁcant reductions were also observed in the proportions
f participants meeting diagnostic criteria for each of the examined
isorders (SAD ≥ 51%, MDD  ≥ 82%, GAD ≥ 52% and PD ≥ 26%), and
he observed reductions in symptoms were maintained from post-
reatment across the 3-month, 12-month and 24-month follow-up
ime points.
The ﬁndings of the present study are consistent with the few
ther studies to directly compare transdiagnostic and disorder-
peciﬁc treatments for the four target disorders of DEP, GAD, PD,f proportions of participants meeting diagnostic criteria and for percentage change.
istic regressions to provide estimates of frequency with 95% conﬁdence intervals
and SAD. This literature has found no marked or consistent differ-
ences between the two  treatment approaches for principal DEP,
GAD and PD (Norton & Barrera 2012; Dear, Gandy et al., 2015;
Dear, Staples et al., 2015; Dear, Zou et al., 2015; Titov, Dear, Staples,
Bennett-Levy et al., 2015; Titov, Dear, Staples, Terides et al., 2015;
Fogliati, Dear et al., 2016). Thus, contrary to what might be expected
and was  hypothesised in this study, transdiagnostic CBT does not
appear to be superior for comorbid DEP, GAD  or PD. This further
supports the observation (Norton and Barrera 2012; Dear, Gandy
et al., 2015; Dear, Staples et al., 2015; Dear, Zou et al., 2015; Titov,
Dear, Staples, Bennett-Levy et al., 2015; Titov, Dear, Staples, Terides
et al., 2015; Fogliati, Dear et al., 2016) that the real beneﬁt of the
transdiagnostic approach may  be more pragmatic than clinical.
That is, while disorder-speciﬁc and transdiagnostic treatments may
be similarly effective and acceptable, transdiagnostic treatments
offer the opportunity to employ one treatment that addresses
symptoms of multiple disorders rather than needing to deliver and
have clinicians competent in numerous speciﬁc programs (McHugh
et al., 2009). This is signiﬁcant in the context of recent calls for
innovation in psychological treatment (e.g., Kazdin and Blasé, 2011;
Kazdin, 2015) and large-scale initiatives to increase access to treat-
ment for common mental health conditions such as SAD (e.g., Titov,
Dear, Staples, Bennett-Levy et al., 2015; Titov, Dear, Staples, Terides
et al., 2015; Richards and Suckling, 2009). There are also the addi-
tional potential beneﬁts of transdiagnostic treatments reducing
the need for complex differential diagnostic assessments (e.g., to
determine principal diagnoses and the most appropriate disorder-
speciﬁc treatment to be provided) and being easier to disseminate
than multiple disorder-speciﬁc treatments (e.g., because of the
reduced need for clinicians to be trained to competence in multiple
disorder-speciﬁc treatment protocols) (McHugh et al., 2009).
This study also found similar clinical outcomes, treatment com-
pletion and satisfaction rates among participants with principal
SAD and other comorbid disorders when internet-delivered CBT
was delivered in both a clinician-guided and self-guided format.
This is consistent with the ﬁndings of the other studies in this
series of RCTs focused on principal MDD  (Titov, Dear, Staples,
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ennett-Levy et al., 2015; Titov, Dear, Staples, Terides et al., 2015),
rincipal GAD (Dear, Gandy et al., 2015; Dear, Staples et al., 2015;
ear, Zou et al., 2015) and principal PD (Fogliati, Dear et al., 2016)
nd the few other recent studies to directly compare CG-CBT and
G-CBT (Berger, Caspar et al., 2011; Berger, Hämmerli, Gubser, &
aspar, 2011; Titov et al., 2013a,b; Dear, Gandy et al., 2015; Dear,
taples et al., 2015; Dear, Zou et al., 2015). It is important to note
hat this ﬁnding of similar outcomes for CG-CBT and SG-CBT is
nconsistent with the ﬁndings of meta-analyses comparing across
tudies of internet-delivered interventions (Andersson & Cuijpers
009; Cuijpers et al., 2009; Andrews et al., 2010; Andersson &
itov 2014), which have found CG-CBT to be superior to SG-CBT.
t is likely that at least two key differences exist between older
elf-guided internet-delivered interventions and newer, more efﬁ-
acious, versions. First, these newer self-guided internet-delivered
nterventions employed telephone assessments that allow triage
nd evaluation of suitability, but also allow participants to ask
uestions about the treatment and allow clinicians to orient and
repare the participant for treatment. Second, many of these stud-
es have also employed interventions that have been carefully
esigned to work in a self-guided format with, for example, all par-
icipants receiving carefully-designed automated emails to guide
nd reinforce their progression through the intervention (Titov
t al., 2013a,b, 2014a,b). More research is needed to understand
hat features are important for effective and safe self-guided inter-
entions, and for whom these interventions are most effective and
ppropriate. However, the ﬁndings of this and other recent studies
ighlight the potential of carefully designed self-guided interven-
ions for increasing access to effective psychological treatment and
educing the burden of common mental health conditions (Kazdin
nd Blasé, 2011; Kazdin, 2015).
The present study has a number of important strengths and lim-
tations that need to be noted and considered when interpreting
ts results. As with the other trials in this series of studies (Dear,
andy et al., 2015; Dear, Staples et al., 2015; Dear, Zou et al., 2015;
itov, Dear, Staples, Bennett-Levy et al., 2015; Titov, Dear, Staples,
erides et al., 2015; Fogliati, Dear et al., 2016), the main limita-
ion of the current trial is the absence of a control group. While
AD symptoms are relatively unremitting and the clinical effects
bserved are unlikely to have occurred as a result of time and other
on-speciﬁc factors alone, the absence of a control group means
he impact of such effects cannot be ruled out or controlled for
n the current study. Another main limitation of the current trial
s that it was designed and conducted as a superiority trial rather
han a non-inferiority trial. Consequently, as with the other tri-
ls (Dear, Gandy et al., 2015; Dear, Staples et al., 2015; Dear, Zou
t al., 2015; Titov, Dear, Staples, Bennett-Levy et al., 2015; Titov,
ear, Staples, Terides et al., 2015; Fogliati, Dear et al., 2016), caution
s needed in concluding the absence or presence of any statistical
ndings as supporting the clinical equivalence of the different treat-
ent apppraoches and support formats. For example, there was
ome evidence of a small statistically signiﬁcant difference favour-
ng CG-CBT over SG-CBT for principal SAD symptoms at 3-month
ollow-up and, while differences were not evident at any other time
oints, non-inferiority trial designs with well-established margins
f non-inferiority are needed to draw ﬁrm conclusions about the
resence or absence of clinically meaningful differences. Other lim-
tations include resource constraints that meant it was  not possible
o blind the diagnostic assessments, administer a broader range of
tandardised measures of social anxiety symptoms, or conduct a
ore exhaustive evaluation of treatment satisfaction and accept-
bility. Some caution is also needed in generalising the ﬁndings
f the current trial. For example, the current study employed one
articular disorder-speciﬁc treatment and one particular transdi-
gnostic treatment and it is not clear whether the current ﬁndings
ould generalise to other treatment protocols, especially deliv- Disorders 42 (2016) 30–44
ered in traditional face-to-face formats. For example, the current
disorder-speciﬁc treatment protocol included controlled breathing
and assertive communication as skills, which are not common parts
of some disorder-speciﬁc face-to-face CBT treatment protocols
for SAD but do often appear in disorder-speciﬁc iCBT treatments
for SAD. Moreover, gold-standard face-to-face CBT for SAD also
often include additional components, such as video-feedback and
imagery rescripting (Clarke et al., 2006; McEvoy, Erceg-Hurn,
Saulsman, & Thibodeau, 2015), which were not included in the cur-
rent study and are not routinely a part of iCBT for SAD. However,
it is also important to note that there has been limited published
agreement on what consistitutes a disorder-speciﬁc versus trans-
diagnostic treatment or the core therapeutic components of each,
especially when delivered via the internet. The current study also
employed interventions that were carefully designed and devel-
oped to function in a self-guided format and the amount of clinician
guidance provided to those recieving CG-CBT was relatively limited.
Thus, it is unclear whether the current ﬁndings would generalise
to other self-guided interventions, and it is possible that superior
outcomes could have been obtained among those recieving CG-CBT
had more clinician guidance been provided. Importantly, despite
these limitations, the noteable strengths of the current trial include
the use of a large sample size, high retention rates, the long-term
follow-up of participants, and the use of multiple outcomes to com-
prehensively evaluate the intervention.
The present trial found large clinical improvements and high
levels of treatment satisfaction whether the treatment for SAD was
transdiagnostic or disorder-speciﬁc and self-guided or clinician-
guided. Clinical improvements in principal symptoms of SAD and
comorbid symptoms were observed across a broad range of clinical
domains and were maintained until 24-month follow-up. Reﬂect-
ing this, large improvements in the proportions of participants
meeting diagnostic criteria for SAD and comorbid MDD, GAD and PD
were observed across the treatment approaches and support for-
mats. Thus, consistent with the other trials in this series of studies
(Dear, Gandy et al., 2015; Dear, Staples et al., 2015; Dear, Zou et al.,
2015; Titov, Dear, Staples, Bennett-Levy et al., 2015; Titov, Dear,
Staples, Terides et al., 2015; Fogliati, Dear et al., 2016), the present
study highlights the public health potential of carefully designed
and delivered internet-delivered psychological treatments for a
range of principal and comorbid common mental health disorders.
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